Bone-targeted therapies in metastatic castration-resistant prostate cancer

LAUR Repository

Show simple item record

dc.contributor.author El-Amm, Joelle
dc.contributor.author Freeman, Ashley
dc.contributor.author Patel, Nihar
dc.contributor.author Aragon-Ching, Jeanny B.
dc.date.accessioned 2017-09-22T11:55:43Z
dc.date.available 2017-09-22T11:55:43Z
dc.date.copyright 2013 en_US
dc.date.issued 2017-09-22
dc.identifier.issn 2090-312X en_US
dc.identifier.uri http://hdl.handle.net/10725/6241
dc.description.abstract Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibiting RANK-L mediated bone resorption. While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium, alpharadin is the first radiopharmaceutical to show significant overall survival benefit. Contemporary therapeutic options including enzalutamide and abiraterone have effects on pain palliation and SREs as well. Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. Emerging therapeutics in mCRPC has resulted in great strides in preventing one of the most significant sources of complications of bone metastases. en_US
dc.language.iso en en_US
dc.title Bone-targeted therapies in metastatic castration-resistant prostate cancer en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle evolving paradigms en_US
dc.author.school SOM en_US
dc.author.idnumber 201603787 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Prostate cancer en_US
dc.journal.volume 2013 en_US
dc.identifier.doi http://dx.doi.org/10.1155/2013/210686 en_US
dc.identifier.ctation El-Amm, J., Freeman, A., Patel, N., & Aragon-Ching, J. B. (2013). Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer, 2013. en_US
dc.author.email joelle.elamm@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.hindawi.com/journals/pc/2013/210686/abs/ en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account